Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 April, 2018 10:11 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Hindustan Copper signs MoU with MOIL - 24-Apr-2018 10:01
Alembic Pharma announces successful USFDA inspection of API facility - 24-Apr-2018 09:48
Bharti Infratel quarterly profit climbs 1.58% - 23-Apr-2018 18:10
Mahindra Powerol launches new range of high power diesel generators - 23-Apr-2018 13:36
Gujarat Ambuja Exports completes 1st phase of greenfield maize processing plant - 23-Apr-2018 12:58
Lupin receives USFDA for generic of Xenazine tablets - 23-Apr-2018 12:52
Indian Overseas Bank signs agreement with NeSL - 23-Apr-2018 10:21
HDFC Bank Q4 net grows 20% to Rs 47.99 bn - 23-Apr-2018 10:17
Indian Hume Pipe Co secures work order worth Rs 5.78 bn - 23-Apr-2018 10:00
Welspun Corp bags contract to supply water pipes in MENA region - 20-Apr-2018 10:17
TVS Motor Company launches TVS XL100 Heavy Duty 'i-Touch Start' - 20-Apr-2018 10:14
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer